CLINICAL ACTIONS:

Lynch syndrome, which has been previously referred to as hereditary non-polyposis colorectal cancer syndrome (HNPCC), increases gynecologic cancer risks namely endometrial, ovarian, and urothelial cancers in addition to colorectal and other associated cancers (gastric or small bowel cancers), glioblastoma, pancreatic or biliary tract cancer, and sebaceous adenocarcinoma. 

Lynch syndrome should be considered in women with personal and/or family histories with features such as

• Personal history of colorectal cancer
  • < age 50 or
  • ≥ age 50 with a 1st degree relative (parent, child or sibling) also having a diagnosis of colorectal cancer or endometrial cancer
• Women with multiple colorectal cancers or colorectal cancer and endometrial cancer
  • Level of suspicion should also be increased if other Lynch syndrome associated cancers are diagnosed in the patient and close relatives
• Colorectal or endometrial cancer tumor profiles that demonstrate deficient mismatch repair, or microsatellite instability (MSI)
  • Genes implicated in Lynch syndrome are known as mismatch repair (MMR) genes
• Women who report a known gene mutation predisposing to cancer in the family
  • Confirm the gene(s) tested and mutation(s) identified

Note: NCCN recommends referral to a genetics service to discuss multi-gene panel testing for anyone with a colorectal cancer diagnosis <50 | Based on emerging data, they also note that genetic testing may be considered for anyone with CRC diagnosed at any age

Lynch Syndrome is Included in ACMG List of ‘Secondary Findings’

• Because medical interventions can prevent severe morbidity and mortality, Lynch syndrome is on the ACMG list of ‘secondary’ findings
• In summary, the ACMG document on reporting such findings makes the following recommendations
  • In the course of genetic testing for research or clinical care, the laboratory may identify variants in genes unrelated to the initial indication for testing, but nevertheless may have important health implications
  • Results of such ‘secondary findings’ should be communicated to the individuals who may benefit from this knowledge
  • An individual can ‘opt out’ of receiving ‘secondary findings’
  • ACMG secondary findings recommend reporting out known or expected pathogenic variants in the following MMR genes: MLH1, MSH2, MSH6, and PMS2

SYNOPSIS:

Lynch syndrome is inherited in an autosomal dominant fashion, however because of variable expressivity and reduced penetrance, the patient’s personal and family history must be carefully assessed. It is important to note earlier ages of onset and multiple cancers that may suggest Lynch syndrome or another hereditary cancer syndrome. It is critical that those at high risk be identified and referred for genetic counseling. Genetic counseling will allow for discussion of appropriate genetic testing, cancer screening and risk reduction options.

KEY POINTS:

• When reviewing the family health history, remember that both the maternal and paternal family histories should both be carefully considered
• Lynch syndrome greatly increases lifetime risk for:
  • Ovarian cancer: 4-24%
    • Average lifetime risk in general population: 1.31%
  • Endometrial cancer: 25-60%
    • Average lifetime risk in general population: 2.78%
  • Colon cancer: 52–82%
    • Average lifetime risk in general population: 4.35% (females), 4.69% (males)
• In the case of ovarian cancer, do not automatically assume BRCA1 or BRCA2 – consider Lynch syndrome and assess for additional clues such as other associated cancers
  • ACOG does address multigene panels and finds that “Genetic testing may be performed using a panel of multiple genes through next-generation sequencing technology”
  • Heritable cancer syndromes may overlap such that a strong family history for ovarian cancer may be the result of a pathogenic variant in BRCA1/2 or genes associated with Lynch Syndrome
• The prospect of hereditary cancer risk can be anxiety provoking for the patient and family members, so it is important to reinforce the importance of information in allowing options for risk reduction and early cancer detection for those at highest risk

Learn more – Primary Sources:

ACMG and NSGC Joint Practice Guidelines: Referral Indications for Cancer Predisposition Assessment

Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges

ACOG and SGO Joint Practice Bulletin 147: Lynch Syndrome (link through SGO.org)

GeneReviews: Lynch Syndrome (Synonyms: HNPCC, Hereditary Non-Polyposis Colon Cancer)

Lynch syndrome in the 21st century: clinical perspectives

Treatment of epithelial ovarian cancer | The BMJ

ACMG ACT Sheet: Colon Cancer (Asymptomatic)

NIH Medline Plus: Lynch syndrome

ACOG Committee Opinion No. 793: Hereditary Cancer Syndromes and Risk Assessment

NCCN: Genetic/Familial High-Risk Assessment: Colorectal 

MLH1: OMIM

MSH2:  OMIM

MSH6: OMIM

PMS2: OMIM

Locate a genetic counselor or genetics services:

Genetic Services Locator-ACMG

Genetic Services Locator-NSGC

Genetic Services Locator-CAGC

Locate a GYN Oncology Specialist:

Gyn Oncology Locator – SGO

Related ObG Topics:

Endometrial Cancer: Beyond The Basics

Screening for Ovarian Cancer – Fantasy or Reality?

Genetic Counseling: Who to Refer and What They Should Expect

What Do You Really Need to Know About Your Patient’s Family History?

Endometrial Hyperplasia – Current Nomenclature and Treatment

Should Women with Endometrial Cancer Receive Universal Screening for Lynch Syndrome?